Search results
GSK's Key Drugs to Drive Sales in a Sluggish Second Half
Zacks via Yahoo Finance· 2 years agoGSK's specialty products like Dovato, Nucala, Trelegy Ellipta, Shingrix are driving sales, making up...
Top Stock Reports for Danaher, Regeneron Pharmaceuticals & Palo Alto Networks
Zacks via Yahoo Finance· 8 hours agoToday's Research Daily features new research reports on 16 major stocks, including Danaher...
GSK Gears Up to Report Q4 Earnings: What's in the Cards?
Zacks via Yahoo Finance· 1 year agoGSK plc. GSK will report fourth-quarter 2022 results on Feb 1, before the opening bell. In the last...
Why Is Glaxo (GSK) Up 6.7% Since Last Earnings Report?
Zacks via Yahoo Finance· 1 year agoA month has gone by since the last earnings report for GSK (GSK). Shares have added about 6.7% in...
AstraZeneca (AZN) Posts Upbeat Data on Lung Cancer Drug Combo
Zacks via Yahoo Finance· 7 months agoData from a late-stage study shows that AstraZeneca's (AZN) Tagrisso combined with chemotherapy cut...
AstraZeneca's (AZN) Asthma Drug Tezepelumab Gets Nod in Europe
Zacks via Yahoo Finance· 2 years agoAstraZeneca's (AZN) Tezspire is the only biologic medicine approved in Europe to treat severe asthma...
GSK Gears Up for Q1 Earnings: Here's What to Expect
Zacks via Yahoo Finance· 1 day agoWe expect GSK's specialty products like Arexvy, Cabenuva, Juluca, Dovato, Nucala, Trelegy Ellipta and Shingrix to drive first-quarter sales performance.
GSK's New Drugs and Pipeline Hold the Key to Growth in 2023
Zacks via Yahoo Finance· 1 year agoGSK's specialty products like Dovato, Nucala, Trelegy Ellipta and Shingrix are likely to drive...
Zacks Industry Outlook Highlights Gilead Sciences, GSK, Immunocore and Syndax Pharmaceuticals
Zacks via Yahoo Finance· 1 year agoFor Immediate Release Chicago, IL – December 28, 2022 – Today, Zacks Equity Research discusses...
GSK Clocks 10% Growth In Q1 Sales Excluding COVID-19 Products, Reaffirms Guidance
Benzinga via Yahoo Finance· 12 months agoGSK plc (NYSE: GSK) reported Q1 FY23 sales of £6.95 billion, down 3% Y/Y on the actual exchange rate...